The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Open accessAbstract
BACKGROUND: Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined. METHODS: We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer (GlaxoSmithKline). Criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. We tabulated all occurrences of myocardial infarction and death from cardiovascular causes. RESULTS: Data were combined by means of a fixed-effects model. In the 42 trials, the mean age of the subjects was approximately 56 years, and the mean baseline glycated hemoglobin level was approximately 8.2%. In the rosiglitazone group, as compared with the control group, the odds ratio for myocardial infarction was 1.43 (95% confidence interval [CI], 1.03 to 1.98; P=0.03), and the odds ratio for death from cardiovascular causes was 1.64 (95% CI, 0.98 to 2.74; P=0.06). CONCLUSIONS: Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. Our study was limited by a lack of access to original source data, which would have enabled time-to-event analysis. Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although our analysis is secondary, reanalyses of clinical trial data have led to the detection of adverse events well after the market entry of major drugs such as rofecoxib and rosiglitazone. [36,37]”
From Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults (2022) · cites this paper as [37]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In one study, 9 the use of rosiglitazone decreased the risk of diabetes in adults with impaired glucose tolerance by 62%; given concerns about cardiovascular safety, 14 however, the Food and Drug Administration has restricted the use of rosig litazone therapy to patients in whom glycemic control cannot be achieved with other medications and who cannot take pioglitazone.”
From Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredIn the citing paper
“a well-publicized meta-analysis of small phase 3 trials suggesting an increase in myocardial ischemic events (odds ratio, 1.43 [95% CI, 1.03–1.98])”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [210]
In the citing paper
“Several meta-analyses have suggested a 30–40% relative increase in risk for myocardial infarction (65,66) with rosiglitazone.”
From Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data
J. Sweeting, M., J. Sutton, A., & C. Lambert, P. (2004) · Statistics in Medicine · doi:10.1002/sim.1761 · Cited by 1,734
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
Bradburn, M. J., Deeks, J. J., Berlin, J. A., & Russell Localio, A. (2007) · Statistics in Medicine · doi:10.1002/sim.2528 · Cited by 938
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D. S. H., Bonow, R. O., Fonseca, V. A., Grundy, S. M., Horton, E. S., Winter, M. L., Porte, D., Semenkovich, C. F., Smith, S. E., et al. (2003) · Circulation · doi:10.1161/01.cir.0000103683.99399.7e · Cited by 831
Goldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1547 · Cited by 790
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D. S. H., Bonow, R. O., Fonseca, V. A., Grundy, S. M., Horton, E. S., Winter, M. L., Porte, D., Semenkovich, C. F., Smith, S. E., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.256 · Cited by 585
Nissen, S. E. (2005) · JAMA · doi:10.1001/jama.294.20.joc50147 · Cited by 552
Self-citationEffect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus
Fonseca, V. A., Rosenstock, J., Patwardhan, R., & Salzman, A. (2000) · JAMA · doi:10.1001/jama.283.13.1695 · Cited by 538
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1210/jc.86.1.280 · DOI
Cited by
Sorted by citations
Items 901–1,000 of 1,024
Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials
Connolly, J. J., Ooka, K., & Lim, J. K. (2018) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00056 · Cited by 58
Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors
Ugusman, A., Kumar, J., & Aminuddin, A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107832 · Cited by 59
Non-Insulin Antidiabetic Therapy in Cardiac Patients: Current Problems and Future Prospects
Fisman, E. Z., Motro, M., & Tenenbaum, A. (2008) · Advances in cardiology · doi:10.1159/000115193 · Cited by 58
Cardiovascular safety profile of currently available diabetic drugs.
Azimova, K., Juan, Z. T. S., & Mukherjee, D. (2014) · PubMed Central · Cited by 58
Hao, G., Niu, X., Gao, D., Wei, J., & Wang, N. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.21 · Cited by 58
Treating Coronary Disease and the Impact of Endothelial Dysfunction
Matsuzawa, Y., Guddeti, R. R., Kwon, T., Lerman, L. O., & Lerman, A. (2014) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2014.10.004 · Cited by 61
Law, M. R., Kawasumi, Y., & Morgan, S. G. (2011) · Health Affairs · doi:10.1377/hlthaff.2011.0172 · Cited by 59
Rosiglitazone reverses tenofovir-induced nephrotoxicity
Libório, A. B., Andrade, L., Pereira, L. V. B., Sanches, T. R., Shimizu, M. H. M., & Seguro, A. C. (2008) · Kidney International · doi:10.1038/ki.2008.252 · Cited by 58
Identification and Treatment of Prediabetes to Prevent Progression to Type 2 Diabetes
Fonseca, V. A. (2007) · Clinical cornerstone · doi:10.1016/s1098-3597(09)60004-1 · Cited by 57
Preiss, D., Sattar, N. A., & McMurray, J. J. V. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.10.019 · Cited by 60
Biller, B. M. K., Colao, A., Petersenn, S., Bonert, V. S., & Boscaro, M. (2010) · BMC Endocrine Disorders · doi:10.1186/1472-6823-10-10 · Cited by 58
Cardiovascular risk and thiazolidinediones—what do meta‐analyses really tell us?
Schernthaner, G.-H., & CHILTON, R. J. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01262.x · Cited by 57
Ketsawatsomkron, P., Lorca, R. A., Keen, H. L., Weatherford, E. T., Liu, X., Pelham, C. J., Grobe, J. L., Faraci, F. M., England, S. K., & Sigmund, C. D. (2012) · Circulation Research · doi:10.1161/circresaha.112.271577 · Cited by 58
HIV and Metabolic, Body, and Bone Disorders
Ali, M. K., Magee, M. J., Dave, J. A., Ofotokun, I., Tungsiripat, M., Jones, T. K., Levitt, N. S., Rimland, D., & Armstrong, W. S. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000256 · Cited by 57
Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes
Xu, J., & Rajaratnam, R. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0499-5 · Cited by 58
Jang, J. Y., Koh, M., Bae, H., An, D. R., Im, H. N., Kim, H. S., Yoon, J., Yoon, H., Han, B. W., Park, S. B., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2017.03.008 · Cited by 59
Tang, Y., Choi, E., Han, W. C., Oh, M., Kim, J. W., Hwang, J., Park, P., Moon, S.-H., Kim, Y.-S., & Kim, E. (2017) · Journal of Medicinal Food · doi:10.1089/jmf.2016.3792 · Cited by 58
Nuclear receptors in podocyte biology and glomerular disease
Agrawal, S., He, C., & Tharaux, P. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00339-6 · Cited by 61
Segrè, A. V., Wei, N., MAGIC Investigators, Altshuler, D., & Florez, J. C. (2014) · Diabetes · doi:10.2337/db14-0703 · Cited by 57
Incretin Therapy and Islet Pathology: A Time for Caution
Kahn, S. E. (2013) · Diabetes · doi:10.2337/db13-0520 · Cited by 56
Signal Detection and Monitoring Based on Longitudinal Healthcare Data
Suling, M., & Pigeot, I. (2012) · Pharmaceutics · doi:10.3390/pharmaceutics4040607 · Cited by 57
Wheeler, S., Moore, K. P., Forsberg, C. W., Riley, K., Floyd, J. S., Smith, N. L., & Boyko, E. J. (2013) · Diabetologia · doi:10.1007/s00125-013-2958-1 · Cited by 56
Kwok, H., Guo, G., Lau, J. K., Cheng, Y., Wang, J., Jiang, Z., Keung, M.-H., Mak, N. K., Yue, P. Y., & Wong, R. N. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.039 · Cited by 57
The Metabolic Syndrome in East Asians
Hoang, K. C., Le, T. V., & Wong, N. D. (2007) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4564.2007.07491.x · Cited by 57
Improving Assessment of Drug Safety Through Proteomics
Williams, S. A., Murthy, A. C., DeLisle, R. K., Hyde, C. L., Mälarstig, A., Ostroff, R. M., Weiss, S. J., Segal, M. R., & Ganz, P. (2017) · Circulation · doi:10.1161/circulationaha.117.028213 · Cited by 58
New-Onset Diabetes Mellitus in the Kidney Recipient
Bloom, R. D., & Crutchlow, M. F. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02650707 · Cited by 59
Greene, S. J., Vaduganathan, M., Khan, M. S., Bakris, G. L., Weir, M. R., Seltzer, J. H., Sattar, N., McGuire, D. K., Januzzi, J. L., Stockbridge, N., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.047 · Cited by 56
Role of Peroxisome Proliferator-Activated Receptor-.GAMMA. in Atherosclerosis - An Update -
Wang, N., Yin, R., Liu, Y., Mao, G., & Fang, X. (2011) · Circulation Journal · doi:10.1253/circj.cj-11-0060 · Cited by 56
Meta‐analysis: Key features, potentials and misunderstandings
Dekkers, O. M. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12153 · Cited by 58
Yang, B., & Papoian, T. (2012) · Journal of Applied Toxicology · doi:10.1002/jat.2813 · Cited by 57
Lonn, E., Gerstein, H. C., Sheridan, P., Smith, S. L., Díaz, R., Mohan, V., Bosch, J., Yusuf, S., & Dagenais, G. R. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.12.072 · Cited by 56
Effect of systemic medications on onset and progression of diabetic retinopathy
Silva, P. S., Cavallerano, J. D., Sun, J. K., Aiello, L. M., & Aiello, L. P. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.122 · Cited by 57
Wei, J., Bhattacharyya, S., Jain, M., & Varga, J. (2012) · The Open Rheumatology Journal · doi:10.2174/1874312901206010103 · Cited by 58
Arck, P., Tóth, B., Pestka, A., & Jeschke, U. (2010) · Biology of Reproduction · doi:10.1095/biolreprod.110.083550 · Cited by 58
Lack of Association Between Thiazolidinediones and Macular Edema in Type 2 Diabetes
Ambrosius, W. T. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.310 · Cited by 56
PPAR‐γ in the Cardiovascular System
Duan, S. Z., Ivashchenko, C. Y., Usher, M. G., & Mortensen, R. M. (2007) · PPAR Research · doi:10.1155/2008/745804 · Cited by 56
Juurinen, L., Kotronen, A., Granér, M., & Yki‐Järvinen, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1825 · Cited by 57
Rosiglitazone — Continued Uncertainty about Safety
Drazen, J. M., Morrissey, S., & Curfman, G. (2007) · New England Journal of Medicine · doi:10.1056/nejme078118 · Cited by 56
Progress and Controversies: Treating Obesity and Insulin Resistance in the Context of Hypertension
McGill, J. B., Haffner, S. M., Rees, T., Sowers, J. R., Tershakovec, A. M., & Weber, M. A. (2009) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2008.00065.x · Cited by 54
Ectopic visceral fat: A clinical and molecular perspective on the cardiometabolic risk
Mathieu, P., Boulanger, M., & Després, J. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9299-3 · Cited by 56
Nusca, A., Tuccinardi, D., Pieralice, S., Giannone, S., Carpenito, M., Monte, L., Watanabe, M., Cavallari, I., Maddaloni, E., Ussia, G. P., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.670155 · Cited by 60
Energy substrate metabolism and oxidative stress in metabolic cardiomyopathy
Chen, Z., Jin, Z., Cai, J., Li, R., Deng, K., Ji, Y., Lei, F., Li, H., Lu, Z., & Li, H. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02269-1 · Cited by 58
In VitroandIn VivoCharacterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist
He, B., Ning, Z., Li, Z. B., Shan, S., Pan, D., Ko, B. C. B., Li, P., Shen, Z., Dou, G., Zhang, B. L., et al. (2012) · PPAR Research · doi:10.1155/2012/546548 · Cited by 55
Are current clinical trials in diabetes addressing important issues in diabetes care?
Lakey, W. C., Barnard, K., Batch, B. C., Chiswell, K., Tasneem, A., & Green, J. B. (2013) · Diabetologia · doi:10.1007/s00125-013-2890-4 · Cited by 55
The Role of Insulin-Sensitizing Agents in the Treatment of Polycystic Ovary Syndrome
Katsiki, N., Georgiadou, E., & Hatzitolios, A. I. (2009) · Drugs · doi:10.2165/00003495-200969110-00001 · Cited by 56
ABC control of diabetes: Survey data from National Diabetes Health Promotion Centers in Taiwan
Yu, N.-C., Su, H.-Y., Tsai, S., Lin, B. J., Shiu, R.-S., Hsieh, Y.-C., & Sheu, W. H. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.02.020 · Cited by 55
Mechanistic systems modeling to guide drug discovery and development
Schmidt, B. J., Papin, J. A., & Musante, C. J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.09.003 · Cited by 59
Rosenstock, J., Niggli, M., & Maldonado‐Lutomirsky, M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01021.x · Cited by 54
Dai, B., Liu, Y., Mei, C., Fu, L., Xiong, X., Zhang, Y., Shen, X., & Hua, Z. (2010) · Clinical Science · doi:10.1042/cs20100113 · Cited by 55
Tebas, P. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31818651e6 · Cited by 55
Activation of PPARγ attenuates LPS-induced acute lung injury by inhibition of HMGB1-RAGE levels
Wang, G., Liu, L., Zhang, Y., Han, D. G., Lu, J., Xu, J., Xie, X., Wu, Y., Zhang, D., Ke, R., et al. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.01.030 · Cited by 58
Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance
Sahu, R. K., Yadav, R., Prasad, P., Roy, A., & Chandrakar, S. (2014) · SpringerPlus · doi:10.1186/2193-1801-3-695 · Cited by 55
Meredith, D., Panchatcharam, M., Miriyala, S., Tsai, Y.-S., Morris, A. J., Maeda, N., Stouffer, G. A., & Smyth, S. S. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.184234 · Cited by 55
Approach to diabetes management in patients with CVD
Lathief, S., & Inzucchi, S. E. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.05.005 · Cited by 55
Recent advances in managing and understanding diabetic nephropathy
Tang, S. C. W., Chan, G. C. W., & Lai, K. N. (2016) · F1000Research · doi:10.12688/f1000research.7693.1 · Cited by 56
Yasmin, S., Capone, F., Laghezza, A., Piaz, F. D., Loiodice, F., Viswanathan, V., Velmurugan, D., Mondal, S. K., Atlı, Ö., Baysal, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14776-0 · Cited by 56
Innovation in Chemistry, Manufacturing, and Controls—A Regulatory Perspective From Industry
Cauchon, N. S., Oghamian, S., Hassanpour, S., & Abernathy, M. J. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.02.007 · Cited by 59
Human pluripotent stem cell-derived cardiomyocytes for studying energy metabolism
Ulmer, B. M., & Eschenhagen, T. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.04.001 · Cited by 55
Itoh, T., & Yamamoto, K. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-007-0251-x · Cited by 55
Update on Diabetes in the Elderly and the Application of Current Therapeutics
Mazza, A. D., & Morley, J. E. (2007) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2007.07.007 · Cited by 55
Gani, O. A. B. S. M. (2008) · Cardiovascular Diabetology · doi:10.1186/1475-2840-7-6 · Cited by 55
The Functions of PPARs in Aging and Longevity
Erol, A. (2007) · PPAR Research · doi:10.1155/2007/39654 · Cited by 54
Complications of Diabetes Therapy
Corathers, S. D., Peavie, S., & Salehi, M. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.06.005 · Cited by 58
Effect of glucose-lowering therapies on heart failure
Nassif, M. E., & Kosiborod, M. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.211 · Cited by 54
Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials
Bailey, C. J., & Marx, N. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13492 · Cited by 56
Goossens, G. H., Moors, C. C. M., van der Zijl, N. J., Venteclef, N., Alili, R., Jocken, J. W. E., Essers, Y. P. G., Cleutjens, J. P. M., Clément, K., Diamant, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039930 · Cited by 54
Potential savings without compromising the quality of care
Norman, C., Zarrinkoub, R., Hasselström, J., Godman, B., Granath, F. N., & Wettermark, B. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02129.x · Cited by 54
Kadoglou, N. P. E., Iliadis, F. S., Sailer, N., Athanasiadou, Z. S., Vitta, I., Kapelouzou, A., Karayannacos, P. E., Liapis, C. D., Alevizos, M., Angelopoulou, N., et al. (2009) · Metabolism · doi:10.1016/j.metabol.2009.09.002 · Cited by 55
Waltmann, M. D., Basford, J. E., Konaniah, E. S., Weintraub, N. L., & Hui, D. Y. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.05.009 · Cited by 56
Repurposing Drugs to Target the Diabetes Epidemic
Turner, N. A., Zeng, X., Osborne, B., Rogers, S., & Ye, J.-M. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.01.007 · Cited by 59
The Pioglitazone Trek via Human PPAR Gamma: From Discovery to a Medicine at the FDA and Beyond
Devchand, P. R., Liu, T., Altman, R. B., FitzGerald, G. A., & Schadt, E. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01093 · Cited by 57
Artemisinin suppresses myocardial ischemia–reperfusion injury via NLRP3 inflammasome mechanism
Wang, F., Gao, Q., Yang, J., Wang, C., Cao, J., Sun, J., Fan, Z., & Fu, L. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03842-3 · Cited by 54
Cornelius, V. R., Perrio, M. J., Shakir, S., & Smith, L. A. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1844 · Cited by 54
Du, Q., Wang, Y.-J., Yang, S., Wu, B., Han, P., & Zhao, Y.-Y. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.681636 · Cited by 53
Vergara-Rodriguez, P., Vibhakar, S., & Watts, J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.07.004 · Cited by 53
Hartmann-Boyce, J., Theodoulou, A., Oke, J. L., Butler, A. R., Bastounis, A., Dunnigan, A., Byadya, R., Cobiac, L. J., Scarborough, P., Hobbs, F. D. R., et al. (2023) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.122.009348 · Cited by 53
Ghosh, R. K., Bandyopadhyay, D., Hajra, A., Biswas, M., & Gupta, A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.02.134 · Cited by 53
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
Avogaro, A., Fadini, G. P., Sesti, G., Bonora, E., & Prato, S. D. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0431-4 · Cited by 53
Synbiotics and Gut Microbiota: New Perspectives in the Treatment of Type 2 Diabetes Mellitus
Jiang, H., Cai, M., Shen, B., Wang, Q., Zhang, T., & Zhou, X. Q. (2022) · Foods · doi:10.3390/foods11162438 · Cited by 56
Redefining the role of thiazolidinediones in the management of type 2 diabetes
Barnett (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4664 · Cited by 53
Adaramoye, O. A. (2013) · African Health Sciences · doi:10.4314/ahs.v12i4.16 · Cited by 53
de Lorgeril, M., Salen, P., Defaye, P., & Rabaeus, M. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-5 · Cited by 53
PROactive: time for a critical appraisal
Betteridge, D. J., DeFronzo, R. A., & CHILTON, R. J. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn114 · Cited by 53
The safety of thiazolidinediones
Tolman, K. G. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.534982 · Cited by 54
Shah, N. K., Deeb, W., Choksi, R. R., & Epstein, B. J. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1010 · Cited by 52
Patient-important outcomes in diabetes—time for consensus
Montori, V. M., Gandhi, G. Y., & Guyatt, G. H. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61489-5 · Cited by 52
Cost and policy implications from the increasing prevalence of obesity and diabetes mellitus
Ryan, J. (2009) · Gender Medicine · doi:10.1016/j.genm.2009.01.002 · Cited by 52
Nocapyrones: α- and γ-Pyrones from a Marine-Derived Nocardiopsis sp.
Kim, Y., Ogura, H., Akasaka, K., Oikawa, T., Matsuura, N., Imada, C., Yasuda, H., & Igarashi, Y. (2014) · Marine Drugs · doi:10.3390/md12074110 · Cited by 53
Merlin, J., Evans, B. A., Dehvari, N., Sato, M., Bengtsson, T., & Hutchinson, D. S. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500251 · Cited by 56
Thiazolidinediones: A 2010 Perspective
Krishnaswami, A., Ravi-Kumar, S., & Lewis, J. M. (2010) · The Permanente Journal · doi:10.7812/tpp/09-052 · Cited by 54
Lee, G., Oh, S., Hwang, S.-S., Yoon, J. W., Kang, S., Joh, H., Kwon, H., Kim, J., & Park, D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177646 · Cited by 55
Preventive Cardiology as a Subspecialty of Cardiovascular Medicine
Shapiro, M. D., Maron, D. J., Morris, P. B., Kosiborod, M., Sandesara, P. B., Virani, S. S., Khera, A., Ballantyne, C. M., Baum, S. J., Sperling, L. S., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1016 · Cited by 55
Non-inferiority trials in cardiology: what clinicians need to know
Leung, J. T., Barnes, S. L., Lo, S. T., & Leung, D. Y. (2019) · Heart · doi:10.1136/heartjnl-2019-315772 · Cited by 53
Mosenzon, O., Raz, I., Scirica, B. M., Hirshberg, B., Stahre, C., Steg, P. G., Davidson, J. A., Öhman, P., Price, D. L., Frederich, B., et al. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2413 · Cited by 51
Chen, B. D., Greenside, P., Paik, H., Sirota, M., Hadley, D., & Butte, A. J. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12009 · Cited by 51
Surrogate markers in clinical trials—Challenges and opportunities
Duivenvoorden, R., de Groot, E., Stroes, E. S. G., & Kastelein, J. J. P. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.12.009 · Cited by 52
Shiomi, Y., Yamauchi, T., Iwabu, M., Okada‐Iwabu, M., Nakayama, R., Orikawa, Y., Yoshioka, Y., Tanaka, K., Ueki, K., & Kadowaki, T. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.622191 · Cited by 52
Jin, S., Park, C. ‐., Cho, Y. M., Ku, B. J., Ahn, C. W., Cha, B. ‐., Min, K. W., Sung, Y., Baik, S. H., Lee, K. W., et al. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12435 · Cited by 52
Neumiller, J. J. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.013 · Cited by 55
Higuchi, A., Ohashi, K., Shibata, R., Sono-Romanelli, S., Walsh, K. X., & Ouchi, N. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.198465 · Cited by 52
Metadata
- Authors
- Nissen, S. E., & Wolski, K.
- Affiliations
- Cleveland Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-14
- Volume
- 356
- Issue
- 24
- Pages
- 2457-2471
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127125241
- Semantic Scholar
- 238422dc26dc6a78cb2b03fad835d7d1f1f95edb
- Cited by
- 4,675
- References
- 29
- Citations by year
- 2026: 62 · 2025: 66 · 2024: 89 · 2023: 117 · 2022: 132 · 2021: 169 · 2020: 175 · 2019: 198 · 2018: 213 · 2017: 222 · 2016: 234 · 2015: 218 · 2014: 259 · 2013: 271 · 2012: 295
- FWCI
- 395.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- public-domain
- Locations
- New England Journal of Medicine (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- rosiglitazone, myocardial infarction, cardiovascular mortality, type 2 diabetes, thiazolidinediones, drug safety, HbA1c
- MeSH terms
- Rosiglitazone, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Middle Aged, Myocardial Infarction, Odds Ratio, Randomized Controlled Trials as Topic, Risk Assessment, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
